
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a top pharmaceutical firm with strong commercial execution and a diverse product portfolio, generating $60 billion in annual sales. While their current growth drivers, such as Prevnar13 and Eliquis, have been successful, potential positive pipeline data is needed for post-LOE growth. However, recent concerns around sustainability integration and strategic actions, such as aggressive cost-cutting, may pose risks to the company's future performance.
Bears say
Pfizer is facing numerous challenges in its business which may negatively impact its stock performance. These include a declining revenue outlook due to lower COVID-19 estimates and increased competition for its top selling products, potential setbacks for its pipeline assets, and increased macro concerns. While the company has potential catalysts in the near future such as upcoming data releases for its pipeline assets and strong 1Q results that could lead to a potential guidance upgrade for 2026, there are still risks and uncertainties surrounding its long-term growth potential. With its slowest growth profile in the industry and a high number of LOEs approaching, Pfizer may face an earnings trough in 2028-29 with limited visibility for future growth.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares